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Cytotoxic activity of the novel Akt inhibitor, MK-2206,
in T-cell acute lymphoblastic leukemia
C Simioni1,8, LM Neri1,8, G Tabellini2, F Ricci3, D Bressanin4, F Chiarini5, C Evangelisti5, A Cani1, PL Tazzari3, F Melchionda6,
P Pagliaro3, A Pession6, JA McCubrey7, S Capitani1 and AM Martelli4,5
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder arising from T-cell progenitors. T-ALL accounts for
15% of newly diagnosed ALL cases in children and 25% in adults. Although the prognosis of T-ALL has improved, due to the use of
polychemotherapy schemes, the outcome of relapsed/chemoresistant T-ALL cases is still poor. A signaling pathway that is
frequently upregulated in T-ALL, is the phosphatidylinositol 3-kinase/Akt/mTOR network. To explore whether Akt could represent a
target for therapeutic intervention in T-ALL, we evaluated the effects of the novel allosteric Akt inhibitor, MK-2206, on a panel of
human T-ALL cell lines and primary cells from T-ALL patients. MK-2206 decreased T-ALL cell line viability by blocking leukemic cells
in the G0/G1 phase of the cell cycle and inducing apoptosis. MK-2206 also induced autophagy, as demonstrated by an increase in
the 14-kDa form of LC3A/B. Western blotting analysis documented a concentration-dependent dephosphorylation of Akt and its
downstream targets, GSK-3a/b and FOXO3A, in response to MK-2206. MK-2206 was cytotoxic to primary T-ALL cells and induced
apoptosis in a T-ALL patient cell subset (CD34þ /CD4 /CD7 ), which is enriched in leukemia-initiating cells. Taken together, our
ﬁndings indicate that Akt inhibition may represent a potential therapeutic strategy in T-ALL.
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INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
malignancy characterized by the accumulation of undifferentiated
thymocytes that have acquired multiple genomic aberrations
affecting critical transcriptional and signaling networks.1–5 Survival
rates at 5 years for children and adolescents with T-ALL are
70–75%, whereas for adults the rates are 35–40%.6,7 Therefore,
there is a need for novel and less toxic treatment strategies
targeting aberrantly activated signaling pathways that increase
proliferation, survival and drug resistance of T-ALL cells.
The phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR signaling
pathway has been shown to have key roles in the proliferation,
survival and drug resistance of cancer cells.8 In particular, Akt
activation and/or overexpression are often associated with
resistance to chemotherapy or radiotherapy.9,10 Consistently,
dominant-negative mutants of Akt enhanced the cytotoxicity of
chemotherapeutic agents.11 Thus, small-molecule inhibitors of Akt
have a great potential for novel forms of cancer treatment.12,13
PI3K/Akt activation is detected in about 85% of T-ALL patients and
portends a poorer prognosis.14,15 Moreover, when a constitutively
active, myristoylated allele of Akt was introduced into murine
hematopoietic cells, mice developed a T-cell lymphoma with
high frequency (65%).16 Of note, the evolution of T-cell lymphoma
to T-ALL was dependent, among other molecular alterations,
also on Akt hyperactivation.17 Hence, there is a strong rationale
for developing novel, molecularly targeted therapies against
Akt in T-ALL.
However, the design of ATP-competitive inhibitors selective for
Akt has proven challenging, although a few of them have been
synthesized and tested in preclinical models of human cancers.18
MK-2206 is a novel, orally active, allosteric Akt inhibitor, which is
under development for the treatment of solid tumors. MK-2206 is
a potent and selective drug for Akt, and its efﬁcacy has been
proven in preclinical models of human cancers.19–21 Remarkably,
MK-2206 displayed modest inhibitory effects on glucose transport
in GLUT4-expressing adipocytes and GLUT1-rich human
erythrocytes.21 This ﬁnding is clinically relevant, as hyper-
glycemia is one of the most feared side effects of Akt inhibition
in vivo. MK-2206 has now entered phase I/II clinical trials for
treating solid tumors and acute myelogenous leukemia (http://
clinicaltrials.gov/ct2/results?term=MK2206).
Here, we documented that MK-2206 was cytotoxic against
T-ALL cell lines and patient primary cells, but barely affected the
proliferation of peripheral blood CD4þ T lymphocytes from
healthy donors and the clonogenic potential of CD34þ cells from
cord blood. Treatment of T-ALL cells with MK-2206 caused cell
cycle arrest in G0/G1 phase of the cell cycle, apoptosis and
autophagy. MK-2206 synergized with doxorubicin in drug-
resistant CEM cells. Remarkably, MK-2206 targeted a T-ALL cell
subset that might be enriched in leukemia-initiating cells (LICs).
Taken together, our ﬁndings suggest that targeting Akt with MK-
2206, alone or in combination with chemotherapeutic drugs, may
be an interesting option for treating T-ALL cases that display
aberrant upregulation of PI3K/Akt signaling.
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MK-2206 was from Selleck Chemicals (Houston, TX, USA). The kits for
magnetic labeling separation of CD4þ or CD34þ cells were obtained from
Miltenyi Biotec (Bergisch Gladbach, Germany). Primary antibodies for
western blotting analysis were obtained from Cell Signaling Technology
(Danvers, MA, USA). Anti-CD34-phycoerythrine, anti-CD4-PC5, anti-CD7-
PC7 and anti-Ser 473 p-Akt-AlexaFluor488 were from Beckman Coulter
(Miami, FL, USA). Interleukin (IL)  2,  4,  7,  9 and  15 were from
Peprotech (Rocky Hill, NJ, USA).
Cell culture and primary samples
The T-ALL cell lines, MOLT-4, CEM-S (drug-sensitive) and CEM-R (CEM
VBL100, drug-resistant cells overexpressing 170-kDa P-glycoprotein) were
grown in RPMI 1640, supplemented with 10% fetal bovine serum
(thereafter complete medium). Patient samples, peripheral blood CD4þ
T lymphocytes from healthy donors and cord blood CD34þ cells were
obtained with informed consent according to institutional guidelines and
isolated using Ficoll-Paque for patient lymphoblasts or magnetic labeling
for CD4þ T lymphocytes and CD34þ cells. T-ALL patient lymphoblasts
(2 106 cells/ml) were cultured in triplicate in ﬂat-bottomed 96-well plates
at 37 1C with 5% CO2. Cultures were carried out for 72 h in complete
medium supplemented with 10 ng/ml IL-7. CD4þ T lymphocytes (105/well)
were cultured in complete medium and stimulated for 48 h with a mixture
of 10mg/ml phytohemagglutinin-M and 50 ng/ml human recombinant IL-2
to induce proliferation. Then, 1 mCi [3H]-thymidine was added, and 16 h
later [3H]-thymidine incorporation was measured, using a liquid scintilla-
tion counter.
Colony assays
The formation of erythroid burst-forming units, colony-forming unit (CFU)-
granulo-macrophage and granulo-erythroid-megakaryocytic-monocytic
CFUs from cord blood CD34þ hematopoietic cells, was assessed as
reported elsewhere,22 while CFU-leukemia assays from primary T-ALL cells
were performed by seeding bone marrow CD34þ cells in 35-mm petri
dishes at 37 1C, 5% CO2 in Iscove’s modiﬁed Dulbecco’s medium
supplemented with 1.0% methylcellulose, 20% fetal bovine serum, 1%
bovine serum albumin and various cytokines, including IL-2 (20 ng/ml), IL-4
(10 ng/ml), IL-7 (10 ng/ml), IL-9 (10 ng/ml) and IL-15 (20 ng/ml). Fourteen
days after initiation of culture, colonies of 50 cells or more were scored
using an inverted microscope.
Cell viability analysis
MTT (3-(4,5-dimethylthythiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays
were performed to assess the sensitivity of cells to drugs, as previously
described.23
Cell cycle analysis
Flow cytometric analysis was performed using a propidium iodide/RNase A
staining according to standard procedures, as described elsewhere.24
Samples were analyzed on an EPICS XL ﬂow cytometer (Beckman Coulter)
with the appropriate software (System II, Beckman Coulter). At least 15 000
events/sample were acquired.
Western blot analysis
This was performed according to standard techniques, as described
elsewhere.25
siRNA downregulation of Bcl-XL
This was performed as previously described,26 using Bcl-XL si-Genome
duplexes D-003458-01-0010 and D-003458-04-0010 from Dharmacon
(Chicago, IL, USA). Scrambled siCONTROL Nontargeting siRNA no. 1
D-001210-01-20 from Dharmacon was used as negative, nonsilencing
control.
Combined drug effect analysis
The combination effect and a potential synergy were evaluated from
quantitative analysis of dose–effect relationship, as described previously.27
For each combination experiment, a combination index number was
calculated using the Biosoft CalcuSyn software (Biosoft, Cambridge, UK).
This method of analysis generally deﬁnes combination index values of
0.9–1.1 as additive, 0.3–0.9 as synergistic ando0.3 as strongly synergistic,
whereas values 41.1 are considered antagonistic.
Flow cytometric analysis of putative T-ALL LIC
This was performed essentially as previously reported.28 To detect
apoptotic cells samples incubated with Annexin V-ﬂuorescein
isothiocyanate. In some cases, cells were permeabilized and stained with
an AlexaFluor 488-conjugated antibody to Ser 473 p-Akt. Samples were
analyzed on a Navios ﬂow cytometer (Beckman Coulter) equipped with
Kaluza software (Beckman Coulter).
Statistical evaluation
The data are presented as mean values from three separate experiments
±s.d. Data were statistically analyzed by a Dunnet test after one-way
analysis of variance at a level of signiﬁcance of Po0.05 vs control samples.
RESULTS
MK-2206 displays cytotoxic pro-apoptotic effects on T-ALL
cell lines
To determine whether MK-2206 could affect viability of T-ALL cell
lines, MOLT-4, CEM-R and CEM-S cells were incubated in the
presence of increasing concentrations of MK-2206 for either 24 or
48 h. Then, the rates of cell survival were analyzed by MTT assays.
The experiments documented that all three cell lines were
sensitive to MK-2206. After 24 h of incubation with the drug, the
IC50 was 2.6 mM for MOLT-4, 4.1 mM for CEM-R and 6.9 mM for CEM-S
cells (data not shown). After 48h of treatment, the cytotoxic effect
was slightly more evident, being the IC50 1.7mM for MOLT-4, 3.3mM
for CEM-R and 5.1mM for CEM-S cells (Figure 1a). To establish
whether the decreased viability was related to apoptosis, extracts
from MOLT-4 and CEM-R cells, treated for 4 h with MK-2206
concentrations ranging from 1 to 10mM, were analyzed by western
blotting, which demonstrated cleavage of procaspase-8, procas-
pase-9, procaspase-3 and of poly(ADP-ribose)polymerase (Figure 1c).
MK-2206 blocks cells in the G0/G1 phase of the cell cycle
Given the importance of the PI3K/Akt/mTOR signaling pathway in
the regulation of cell proliferation,29 the effects of MK-2206 on cell
cycle progression were also investigated. MOLT-4 cells were
treated with MK-2206 for 24 h. Flow cytometric analysis of
propidium iodide-stained cells documented a concentration-
dependent increase in cells in the G0/G1 phase of the cell cycle
and a concomitant decrease in cells in both S and G2/M phase
(Figure 1b).
Overall, these ﬁndings demonstrated that MK-2206 potently
reduced the growth of T-ALL cell lines and that this effect was due
to apoptosis and G0/G1 cell cycle arrest.
MK-2206 affects PI3K/Akt/mTOR signaling in T-ALL cell lines
As MK-2206 is an allosteric Akt inhibitor, it was analyzed whether
treatment with this drug resulted in downregulation of Akt
phosphorylation. Upon 4 h of incubation with MK-2206, a
concentration-dependent decrease in both Thr 308 and Ser 473
p-Akt levels was detected in all the cell lines analyzed (Figure 2a).
Total Akt levels were unaffected by MK-2206. Akt inhibition had
functional consequences on the phosphorylation levels of two
well-established Akt substrates, GSK3-a/b and FoxO3A. Both of
these proteins displayed dephosphorylation at amino acidic
residues (Ser 21/9 for GSK3-a/b and Thr-32 for FoxO3A) that are
targeted by Akt. In contrast, expression of total GSK3-a/b and
FoxO3A was unaffected by treatment with MK-2206.
MK-2206 affected also mTOR complex 1 (mTORC1) activity, as it
dephosphorylated p70S6K on Thr 389 and 4E-BP1 on Thr 37/46.
MK-2206 also diminished mTOR complex 2 (mTORC2) activity, as
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documented by a decrease in the levels of Ser 2481 p-mTOR, a
readout for mTORC2 activity (Figure 2b).
MK-2206 induces autophagy
It has been reported that MK-2206 induces autophagy in human
glioma cells and this protected tumor cells against apoptosis.20
Therefore, we investigated whether MK-2206-induced autophagy
also in T-ALL cell lines. MK-2206 increased the amount of cleaved
(14-kDa form) LC3A/B, a well-established autophagy marker
(Figure 3a). Interestingly, the increased cleavage was detected
by western blot in MOLT-4 and CEM-S, but not in CEM-R cells.
Beclin-1, an essential initiator of autophagy, interacts with BH3
domain proteins such as Bcl-2, Bcl-XL and Mcl-1 and these
interactions could inhibit beclin-1-mediated induction of auto-
phagy.30 Therefore, the expression levels of Bcl-2, Bcl-XL and Mcl-1
were investigated by western blot in CEM-R and CEM-S cells.
Although we did not detect major differences between Bcl-2 and
Mcl-1, Bcl-XL was expressed to a much higher extent in CEM-R
when compared with CEM-S cells (Supplementary Figure S1).
Bcl-XL levels were then downregulated by siRNA in CEM-R cells
and the cleavage of LC3A/B was investigated by western blot. In
Figure 3b, we document that speciﬁc siRNA (but not scrambled
siRNA) to Bcl-XL lowered the levels of Bcl-XL in CEM-R cells.
Moreover, when cells treated with BCL-XL-speciﬁc siRNA were
treated with MK-2206, the cleavage of LC3A/B was much more
evident than in cells treated with scrambled siRNA. Overall, these
ﬁndings demonstrated that the levels of Bcl-XL are important for
determining the induction of MK-2006-dependent autophagy in
CEM-R cells.
We then inhibited autophagy using either baﬁlomycin A1 or
chloroquine and measured cell viability by MTT assays. Both
baﬁlomycin A1 and chloroquine, when used alone, displayed only
limited cytotoxic effects against CEM-S cells. However, when they
were combined with MK-2206, it was possible to detect an
increased cytotoxicity in CEM-S cells (Figure 3c). Overall, these
ﬁndings suggested that autophagy could protect T-ALL cells by
the cytotoxic effects of an Akt inhibitor.
MK-2206 synergizes with doxorubicin
We examined whether MK-2206 could synergize with
the anthracycline antibiotic, doxorubicin. Doxorubicin is frequen-
tly included in established protocols to treat T-ALL patients.31 Two
different strategies were explored to determine whether synergy
occurred. In the ﬁrst protocol, T-ALL cell lines were incubated with
both MK-2206 and doxorubicin in combination for 48 h. In the
second protocol, one drug was added before the other, the ﬁrst
drug was administered for 48 h (throughout the entire
experiment) while the second drug was added only for the last
24 h of treatment. In all the experiments, the drugs were used at a
ﬁxed ratio (doxorubicin: MK-2206, 1:30 for MOLT-4 cells and 1:1 for
CEM-R cells). MTT assays were then performed. In MOLT-4 cells,
synergistic effects were observed when MK-2206 was added
with doxorubicin together at low concentrations (10–30 nM of
doxorubicin) after 48 h of treatment. Also in MOLT-4 cells, both of
the sequential treatments resulted in synergistic results, that is,
synergy was observed when MK-2206 was added ﬁrst and
doxorubicin was added second, or when doxorubicin was added
ﬁrst and MK-2206 was added second (Figure 4a).
Figure 1. MK-2206 is cytotoxic to T-ALL cell lines and induces cell cycle arrest and apoptosis. (a) MTT assay of T-ALL cell lines treated with
increased concentrations of MK-2206 for 48 h. (b) MOLT-4 cells were treated with increasing concentrations of MK-2206 for 24 h. Then cell
cycle analysis was performed by flow cytometry. MK-2206 treatment resulted in an increase in cells in the G0/G1 phase and in a decrease in
cells in S phase. CTRL, control (untreated) cells. Asterisks indicate significant differences compared with CTRL. In (a) and (b) results are mean of
three different experiments±s.d. (c) Western blot analysis documenting caspase-8, -9, -3 and poly(ADP-ribose)polymerase cleavage in MOLT-4
and CEM-R cells, treated for 4 h with MK-2206. Antibody to b-actin served as a loading control.
Figure 2. Effects of MK-2206 on the phosphorylation status of critical
components of the PI3K/Akt/mTOR signaling pathway. (a) Western
blot analysis for Akt, GSK3 a/b and FoxO3A. (b) Western blot analysis
for mTOR and its downstream targets, p70S6K and 4E-BP1. In (a) and
(b), MK-2206 treatment was for 4 h, and b-actin served as a loading
control.
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In contrast, different results were observed with the drug-
resistant CEM-R cell line. Namely, if the two drugs were
administered together for 48 h, synergism was observed at
concentrations of doxorubicin ranging from 2.5 to 7 mM. In the
sequential exposure experiments, synergy was dependent upon
which drug was added ﬁrst. When MK-2206 was added after
doxorubicin treatment, synergism was detected at all the
concentrations tested. In contrast, when the reverse sequence
was performed, where cells were exposed to MK-2206 for 48 h
followed by post-treatment with doxorubicin for 24 h, antagonism
was frequently observed (Figure 4b). Thus, in the drug-resistant
CEM-R cells, addition of doxorubicin for the entire period was
required to detect synergy with the Akt inhibitor MK-2206.
T-ALL lymphoblasts are sensitive to MK-2206
To better assess the efﬁcacy of the inhibitors as potential
therapeutic agents in T-ALL, we examined six T-ALL pediatric
patient samples isolated from bone marrow, for their sensitivity to
MK-2206. All of the patients displayed enhanced phosphorylation
of Ser 473 p-Akt (data not shown). T-ALL lymphoblast samples,
cultured in the presence of IL-7, which functions as a powerful
proliferative stimulus for these cells,32,33 were treated with
increasing concentrations of MK-2206, and cell survival was
analyzed by MTT assays. A marked reduction in cell viability at
72 h was detected. Under these conditions, the MK-2206 IC50 for
patient samples ranged between 0.75 and 1.35 mM (Figure 5a). In
contrast, CD4þ T lymphocytes isolated from the peripheral blood
of healthy donors and stimulated with phytohemagglutinin-M
plus IL-2 were much less sensitive to MK-2206 concentrations up
to 10 mM, as far as their proliferation (assayed by [3H]-thymidine
incorporation) was concerned (Figure 5b). Overall, these ﬁndings
demonstrated that MK-2206 reduced the growth of T-ALL primary
cells. Moreover, they also suggested that the drug could have a
favorable therapeutic index, as it affected proliferation of normal
CD4þ T lymphocytes to a much lower extent.
MK-2206 inhibits the clonogenic growth of T-ALL progenitors
without affecting normal hematopoiesis
Clonogenic cultures of primary T-ALL were generated from
CD34þ cells treated with 0.5–5.0 mM MK-2206. The levels of CFU-
leukemia formation from three different T-ALL samples were
markedly reduced with a mean decrease from 63 to 21%, after
treatment with 0.5–5.0 mM MK-2206 (Figure 5c). In contrast, MK-
2206 did not affect in a statistically signiﬁcant manner the
clonogenic growth and differentiation of cord blood CD34þ
hematopoietic progenitors, even at the maximal concentration of
5.0 mM. Indeed, the number of the erythroid burst-forming units, or
granulo-monocytic (CFU-granulo-macrophage), or granulocyte,
erythroid, macrophage and megakaryocyte (CFU-granulo-
erythroid-megakaryocytic-monocytic), colonies was not signiﬁ-
cantly decreased by the drug (Figure 5c).
MK-2206 affects PI3K/Akt signaling in T-ALL patient samples
T-ALL lymphoblast samples, cultured as described above, were
treated with 1 mM MK-2206 for 48 h and then analyzed by western
blot. In all the patients analyzed (n¼ 5), the drug induced a
downregulation of Akt phosphorylation (Figure 5d).
MK-2206 dephosphorylates Akt and induces apoptosis in the
CD34þ /CD7 /CD4 subset of patient lymphoblasts
Finally, we investigated whether MK-2206 could dephosphorylate
Akt and induce apoptosis in a T-ALL patient lymphoblast
subpopulation (CD34þ /CD7 /CD4 ), which is enriched in puta-
tive LIC,34 using quadruple staining and ﬂow cytometric analysis.
After electronic gating on the CD7 /CD4 lymphoblast subset,
cells were analyzed for CD34þ expression and positivity to either
Ser 473 p-Akt or Annexin V-ﬂuorescein isothiocyanate staining.
After 48 h of treatment, the drug markedly dephosphorylated Akt
at Ser 473 (Figure 6a) and induced apoptosis in the CD34þ /CD7 /
CD4 subpopulation, as documented by Annexin-V ﬂuorescein
isothiocyanate staining (Figure 6b).
DISCUSSION
The PI3K/Akt/mTOR signaling cascade is a pivotal pathway that is
deregulated in a wide variety of human cancers and strongly
contributes to both tumorigenesis and therapy resistance.
Considering the crucial role had by aberrantly activated Akt in
the pathogenesis of T-ALL,16,17 we studied the efﬁcacy of MK-
2206, a novel allosteric Akt inhibitor,19 as a potential therapeutic
agent. MK-2206 decreased the viability of T-ALL cell lines, in a
concentration-dependent manner. All these cell lines are
Figure 3. MK-2206 induces autophagy and siRNA downregulation increases MK-2206-dependent cleavage of LC3A/B. (a) Western Blot analysis
for LC3A/B in MOLT-4, CEM-R and CEM-S cells. Cells were treated with MK-2206 for 4 h. (b) The levels of Bcl-XL were downregulated by a 48-h-
long treatment with siRNA, then cells were incubated for 4 h with 4 mM MK-2206 and western blot analysis was performed. In (a) and (b),
b-actin served as a loading control. (c) MTT assays documenting the effects of bafilomycin A1 (4mM) or chloroquine (25mM) on viability of CEM-
S cells treated for 24 h with MK-2206 (4 mM). Results are mean of three different experiments±s.d. Asterisks indicate significant differences
compared with CTRL (untreated cells).
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Figure 4. Synergistic effects of the MK-2206 plus doxorubicin combination in MOLT-4 and CEM-R cells. (a) MOLT-4 cells were treated for 48 h
with MK-2206 or doxorubicin, either alone, in combination or in sequential exposure (relative concentration ratio, MK-2206:doxorubicin, 30:1).
(b) CEM-R cells were treated for 48 h with MK-2206 and doxorubicin, alone, in combination or in sequential exposure (relative concentration
ratio, MK-2206:doxorubicin, 1:1). Viability was then analyzed by MTT assays. Results are mean of three different experiments±s.d.
Combination index (CI) value for each data point was calculated with the appropriate software for dose effect analysis.
Figure 5. MK-2206 is cytotoxic to primary T-ALL cells. (a) Three representative T-ALL patient lymphoblast samples, cultured in the presence of
IL-7, were treated with increasing concentrations of MK-2206 for 72 h. Cell viability was then analyzed by MTT assays. (b) CD4þ T lymphocytes,
isolated from the peripheral blood of healthy donors, stimulated with phytohemagglutinin-M plus IL-2 for 72 h, were assayed for their
proliferation by [3H]-thymidine incorporation in the presence of MK-2206. (c) Clonogenic activity of CD34þ cells from three representative
T-ALL patients or from cord blood CD34þ cells obtained from three healthy donors. Cells were cultured for 14 days, then colony formation
was assessed under an inverted microscope. In (a–c), results are mean of three different experiments±s.d. Asterisks indicate significant
differences compared with CTRL (untreated samples). (d) Western blot analysis on T-ALL lymphoblast samples cultured as in a. In all three
patients, the phosphorylation status of Ser 473 p-Akt was tested before and after MK-2206 (1 mM for 48 h) treatment in vitro.
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phosphatase and tensin homologue deleted on chromosome 10
negative and display a nonfunctional p53 pathway.35 The efﬁcacy
of MK-2206 in decreasing the viability of T-ALL cell lines was due
to both cell cycle arrest and caspase-dependent apoptosis.
MK-2206 dephosphorylated Akt on both Thr 308 and Ser 473, its
downstream targets, GSK3a/b and FoxO3A and two mTORC1
downstream targets, that is, p70S6K and 4EB-P1. Downregulation of
Ser 2448 p-mTOR levels were indicative of an inhibition of mTORC1
(data not shown), whereas decreased phosphorylation of Ser 473
p-Akt indicated an indirect targeting of mTORC2 by MK-2206.
The mechanisms that control mTORC2 activity have only begun
to be revealed. mTORC2 activation requires PI3K and the TSC1/
TSC2 complex.36 As Akt is upstream of TSC1/TSC2, MK-2206, by
inhibiting Akt, could also downregulate mTORC2 activity.
In addition to apoptosis, MK-2206 caused autophagy in T-ALL
cell lines. Autophagy induction by MK-2206 could be related to
mTORC1 inhibition, as mTORC1 inhibits autophagy through
phosphorylation of two autophagy-promoting factors, unc-51-like
kinase 1 and autophagy-related gene 13.37 However, the
induction of autophagy, as indicated by cleavage of LC3A/B, was
much stronger in MOLT-4 and CEM-S cells than in drug-resistant
CEM-R cells. As downregulation of Bcl-XL by siRNA increased
LC3A/B cleavage in CEM-R cells, we could infer that the differential
induction of autophagy in CEM-R vs CEM-S cells was related to the
fact that CEM-R cells express Bcl-XL to a much higher extent than
CEM-S cells. This observation is consistent with ﬁndings obtained
in other cell types.38
Autophagy is a lysosomal degradation pathway that is
essential for survival, differentiation development and homeo-
stasis. Tumor cells can exploit autophagy as a survival mechanism
to tolerate metabolic stress and to contrast apoptosis.39
Interestingly, both baﬁlomycin A1 and chloroquine, two
inhibitors of autophagy, sensitized CEM-S cells to MK-2206, by
increasing apoptosis. This ﬁnding demonstrated that autophagy is
a prosurvival mechanism that protected CEM-S cells from MK-
2006-induced apoptosis. Therefore, the use of autophagy
inhibitors in combination with MK-2006 should be considered in
future clinical trials.
We have also documented that MK-2206 synergized with
doxorubicin. Analysis of the results demonstrated that in MOLT-4
the synergism of MK-2206 with doxorubicin was relevant at low
concentrations (10–30 nM of doxorubicin) at 48 h of treatment. The
sequential exposure to MK-2206 after doxorubicin treatment for a
total of 48 h resulted in relevant synergism at concentrations
ranging from 10 to 100 nM doxorubicin, with an even stronger
synergism using the reverse sequence. In CEM-R cell line, if the
two drugs were administered together for 48 h, the synergism was
evident at intermediate concentrations. The sequential exposure
to MK-2206 after doxorubicin treatment for a total of 48 h resulted
in relevant synergism (Figure 4b). We are presently investigating
the reasons that could explain these ﬁndings. Nevertheless, it is
remarkable that in MOLT-4 cells a synergism was detected at
concentrations that were well below the MK-2206 IC50 for this cells
line. This ﬁnding could have a clinical relevance for T-ALL patients,
as a combination of MK-2206 and doxorubicin increased the
cytotoxic activity of MK-2206 and allowed for the use of a much
lower concentration of the inhibitor. This could considerably
attenuate the possible MK-2206 toxic side effects. However, MK-
2206 is generally well tolerated at doses that result in plasma
concentrations portending activity in preclinical models.40 MK-
2206 demonstrated marked anti-leukemic effects in vitro against
T-ALL patient lymphoblasts. The cytotoxic effects were speciﬁc to
leukemic cells, as the drug only slightly affected the proliferation
of CD4þ T lymphocytes from healthy donors. Moreover, MK-2206
spared normal hematopoiesis in vitro, while it affected the
clonogenic activity of T-ALL CD34þ cells. Taken together, these
ﬁndings suggest that MK-2206 could result in a favorable
therapeutic window also in vivo.
The difﬁculty in eradicating tumors might result from the
conventional treatments targeting the bulk of the tumor cells, but
not LICs.41 Therefore, strategies aimed to eliminating these cells
could have signiﬁcant clinical implications. Of note, MK-2206
dephosphorylated Akt and induced apoptosis in a T-ALL
lymphoblast subpopulation (CD34þ /CD7 /CD4 ), which has
been reported to be enriched in LIC in pediatric patients.34
In conclusion, our preclinical ﬁndings strongly suggest that MK-
2206, either alone or combined with traditional chemotherapeutic
drugs, could be a valuable compound for treating those T-ALL
patients displaying activation of PI3K/Akt signaling and who are
still facing a poor prognosis.
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